Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD

Articles by Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD

$Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.$

JNJ-4496 Prevents Antigen Escape, May Work as Salvage Therapy in R/R LBCL

ByMatthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD

June 25th 2025

Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.

Latest Updated Articles

$Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.$
JNJ-4496 Prevents Antigen Escape, May Work as Salvage Therapy in R/R LBCL
June 25th 2025

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)